The Impact of Magnesium Oxide Monohydrate Compared to Placebo on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients
Who is this study for? Patients with Magnesium Deficiency, Heart Failure
What treatments are being studied? Magnesium Oxide
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Magnesium supplementation could improve cardiac performance. Patients with chronic heart failure (CHF) are magnesium deficient and we hypothesized that 1 year supplementation of oral magnesium comparted to placebo will improve exercise duration time and quality of life.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• CHF patients NYHA II-IV \> 3 months
• Diuretic therapy \> 3 months
• Signed informed consent
Locations
Other Locations
Israel
Leviev Heart Center, Chaim Sheba Medical Center
RECRUITING
Ramat Gan
Contact Information
Primary
Michael Shechter, MD
Michael.Shechter@sheba.health.gov.il
+97235302617
Backup
Nava Eizenberg, RN
Nava.Eizenberg@sheba.health.gov.il
+97235302617
Time Frame
Start Date: 2019-08-25
Estimated Completion Date: 2026-03-01
Participants
Target number of participants: 320
Treatments
Active_comparator: Magnesium
oral magnesium oxide tablets \[Magnox 520 TM (magnesium oxide monohydrate, 520 mg/day of elemental magnesium), Naveh Pharma, Israel\]
Placebo_comparator: Placebo
Placebo tablets
Related Therapeutic Areas
Sponsors
Collaborators: Naveh Pharma (1996) Ltd.
Leads: Sheba Medical Center